Subscribe to RSS
DOI: 10.1055/s-0043-1772695
Evaluation of an Objective MRI-Based Tumor Regression Grade (mrTRG) Score and a Subjective Likert Score for Assessing Treatment Response in Locally Advanced Rectal Cancers—A Retrospective Study
Abstract
Purpose: Magnetic resonance imaging (MRI) with the help of MRI-based tumor regression grade (mrTRG) score has been used as a tool to predict pathological tumor regression grade (pTRG) in patients of rectal cancer post-neoadjuvant chemoradiation. Our study aims to evaluate the ability of MRI in assessing treatment response comparing an objective mrTRG score and a subjective Likert score, with a focus on the ability to predict pathologic complete response (pCR).
Methods: Post-treatment MRI studies were retrospectively reviewed for 170 consecutive cases of histopathologically proven rectal cancer after receiving neoadjuvant chemoradiation and prior to surgery by two oncoradiologists blinded to the eventual postoperative histopathology findings. An objective (mrTRG) and a subjective Likert score were assigned to all the cases. Receiver operating characteristic curves were constructed to determine the ability of Likert scale and mrTRG to predict pCR, with postoperative histopathology being the gold standard. The optimal cutoff points on the scale of 1 to 5 were obtained for mrTRG and Likert scale with the greatest sum of sensitivity and specificity using the Youden Index.
Results: The most accurate cutoff point for the mrTRG to predict complete response was 2.5 (using Youden index), with a sensitivity of 69.2%, specificity of 69.6%, positive predictive value (PPV) of 85.6%, negative predictive value (NPV) of 46.4%, and accuracy of 69.3%. The most accurate cutoff for the Likert scale to predict complete response was 3.5, with a sensitivity of 47.5%, specificity of 89.1%, PPV of 91.9%, NPV of 39.4%, and accuracy of 59%. mrTRG had a lower cutoff and was more accurate in predicting pCR compared to Likert score.
Conclusion: An objective mrTRG was more accurate than a subjective Likert scale to predict complete response in our study.
Publication History
Article published online:
12 September 2023
© 2023. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol 2013; 3: 262
- 2 Santos MD, Silva C, Rocha A, Matos E, Nogueira C, Lopes C. Prognostic value of Mandard and Dworak tumor regression grading in rectal cancer: study of a single tertiary center. ISRN Surg 2014; 2014: 310542
- 3 Roy P, Serra S, Kennedy E, Chetty R. The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy. J Surg Oncol 2012; 105 (02) 130-134
- 4 Patel UB, Taylor F, Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29 (28) 3753-3760
- 5 Patel UB, Brown G, Rutten H. et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2012; 19 (09) 2842-2852
- 6 Patel UB, Blomqvist LK, Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response–the MERCURY experience. Am J Roentgenol 2012; 199 (04) W486-95
- 7 Shihab OC, Taylor F, Salerno G. et al. MRI predictive factors for long-term outcomes of low rectal tumours. Ann Surg Oncol 2011; 18 (12) 3278-3284
- 8 Rosenkrantz AB, Kim S, Lim RP. et al. Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 2013; 269 (02) 482-492
- 9 Khorasani S. et al. Principles of Adjuvant and Neoadjuvant Therapy for Locally Advanced Rectal Cancer. In: Chang GJ. ASCRS Textbook of Colon and Rectal Surgery. 3rd ed.. New York: Springer; 2016
- 10 Habr-Gama A, Sabbaga J, Gama-Rodrigues J. et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?. Dis Colon Rectum 2013; 56 (10) 1109-1117
- 11 Arya S, Das D, Engineer R, Saklani A. Imaging in rectal cancer with emphasis on local staging with MRI. Indian J Radiol Imaging 2015; 25 (02) 148-161
- 12 van der Valk M. The International Watch & Wait database (IWWD) for rectal cancer: An update. J Clin Oncol 2017; 35 (04) 521
- 13 Mandard A-M, Dalibard F, Mandard J-C. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73 (11) 2680-2686
- 14 Siddiqui MRS, Bhoday J, Battersby NJ. et al. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol 2016; 22 (37) 8414-8434
- 15 Voogt ELK, Nordkamp S, van Zoggel DMGI. et al. MRI tumour regression grade in locally recurrent rectal cancer. BJS Open 2022; 6 (03) zrac033
- 16 Sclafani F, Brown G, Cunningham D. et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer 2017; 117 (10) 1478-1485
- 17 Arslan A, Turk G, Karagöz Eren S. et al. Compatibility of MRI and pathological tumor regression grading in patients with locally advanced rectal cancer after undergoing neoadjuvant chemoradiotherapy. Turk Onkol Derg 2021; 36 (04) 468-477
- 18 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Annals of Surgery 2004; 240: 711-717 PubMed
- 19 Maas M, Nelemans PJ, Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11 (09) 835-844
- 20 Hughes R, Glynne-Jones R, Grainger J. et al. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?. Int J Colorectal Dis 2006; 21 (01) 11-17
- 21 Shivnani AT, Small Jr W, Stryker SJ. et al. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg 2007; 193 (03) 389-393 , discussion 393–394
- 22 Nahas SC, Nahas CSR, Cama GM. et al. Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer. Abdom Radiol (NY) 2019; 44 (11) 3632-3640
- 23 Jang JK, Choi SH, Park SH. et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy. Eur Radiol 2020; 30 (04) 2312-2323
- 24 Jang JK, Lee JL, Park SH. et al. Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer. Br J Surg 2018; 105 (12) 1671-1679
- 25 Fayaz MS, Demian GA, Fathallah WM. et al. Significance of magnetic resonance imaging-assessed tumor response for locally advanced rectal cancer treated with preoperative long-course chemoradiation. J Glob Oncol 2016; 2 (04) 216-221
- 26 Lee MA, Cho SH, Seo AN. et al. Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal cancer. Am J Roentgenol 2017; 209 (06) 1247-1255
- 27 van den Broek JJ, van der Wolf FSW, Lahaye MJ. et al. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation. Dis Colon Rectum 2017; 60 (03) 274-283
- 28 Aker M, Boone D, Chandramohan A, Sizer B, Motson R, Arulampalam T. Diagnostic accuracy of MRI in assessing tumor regression and identifying complete response in patients with locally advanced rectal cancer after neoadjuvant treatment. Abdom Radiol (NY) 2018; 43 (12) 3213-3219
- 29 Shia J, McManus M, Guillem JG. et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol 2011; 35 (01) 127-134
- 30 Wu LM, Zhu J, Hu J. et al. Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer?. Int J Colorectal Dis 2013; 28 (09) 1225-1238
- 31 van der Paardt MP, Zagers MB, Beets-Tan RGH, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013; 269 (01) 101-112
- 32 Hein PA, Kremser C, Judmaier W. et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003; 45 (03) 214-222
- 33 Allen SD, Padhani AR, Dzik-Jurasz AS, Glynne-Jones R. Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. Am J Roentgenol 2007; 188 (02) 442-451